Search Results
You are looking at 1 - 1 of 1 items for :
- Author: Philippe Touraine x
- Adrenal x
Search for other papers by Dafydd Aled Rees in
Google Scholar
PubMed
Search for other papers by Deborah P Merke in
Google Scholar
PubMed
Search for other papers by Wiebke Arlt in
Google Scholar
PubMed
Search for other papers by Aude Brac De La Perriere in
Google Scholar
PubMed
Search for other papers by Angelica Linden Hirschberg in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John Newell-Price in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Nike M Stikkelbroeck in
Google Scholar
PubMed
Search for other papers by Philippe A Touraine in
Google Scholar
PubMed
Search for other papers by Alex Lewis in
Google Scholar
PubMed
Search for other papers by John Porter in
Google Scholar
PubMed
Search for other papers by Helen Coope in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Background
Prednisolone and prednisone are recommended treatment options for adults with congenital adrenal hyperplasia (CAH); however, there is no randomised comparison of prednis(ol)one with hydrocortisone.
Design
Six-month open-label randomised phase 3 study and interim analysis of a single-arm extension study was the design of the study.
Methods
The method of the study was hydrocortisone dose equivalent and 09:00-h 17-hydroxyprogesterone (17OHP) from 48 patients taking prednis(ol)one at baseline.
Results
At baseline, the median hydrocortisone dose equivalent was 30 mg/day and 17OHP was < 36 nmol/L (3× upper limit of normal) in 56% of patients. Patients were randomised to continue prednis(ol)one or switch to modified-release hydrocortisone capsule (MRHC) at the same hydrocortisone-equivalent dose. At 4 weeks, 94% on MRHC and 71% on prednis(ol)one had 17OHP < 36 nmol/L. At 18 months in the extension study of MRHC, the median MRHC dose was 20 mg/day and 82% had 17OHP < 36 nmol/L. The per cent of patients with 17OHP < 36 nmol/L on a hydrocortisone dose equivalent ≤ 25 mg/day was greater at 18 months in the extension study on MRHC than while on prednis(ol)one at baseline: 57% vs 27%, P = 0.04. In the randomised study, no patients had an adrenal crisis on MRHC and one on prednisolone. In the extension study (221 patient years), there were 12 adrenal crises in 5 patients (5.4/100 patient years).
Conclusion
MRHC reduces 17OHP at 09:00 h compared to prednis(ol)one and the dose of MRHC can be down-titrated over time in the majority of patients.
